Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia XLH
The FDA Orphan Drug Designation provides significant advantages to investors by granting Anzor Pharmaceuticals valuable development inc...